-
Patient With Newly Diagnosed Multiple Myeloma Considering Lenalidomide-Based Therapy
-
Before dosing: define treatment phase, frailty, CrCl and VTE risk
Confirm newly diagnosed multiple myeloma and the planned lenalidomide-containing regimen. Define treatment phase: combination therapy versus post-ASCT maintenance. Calculate creatinine clearance (CrCl) using Cockcroft-Gault. Assess ECOG performance status, frailty, comorbidities and marrow reserve. Review concomitant medications and baseline thromboembolic risk. Confirm pregnancy-prevention / Lenalidomide REMS requirements when applicable. Additional Considerations: • Treatment phase matters: combination therapy (induction/consolidation in TE or TI patients) vs post-ASCT maintenance use different dosing schedules. • Individualize dose based on age, frailty, marrow reserve, infection risk, and comorbidities. • Adjust for drug interactions and tolerability.
-
Post-ASCT maintenance: choose dose by CrCl
Initiate lenalidomide maintenance after adequate hematologic recovery following auto-HSCT. • Standard starting dose with CrCl >60 mL/min: 10 mg once daily continuously on Days 1–28 of repeated 28-day cycles. • May increase to 15 mg once daily after 3 cycles if tolerated. • For CrCl ≤60 mL/min, use the renal-adjusted maintenance doses shown in the branches below. • Continue until disease progression or unacceptable toxicity. • Maintenance dosing is different from lenalidomide combination-therapy dosing and should remain a separate pathway.
-
CrCl >60 → 10 mg once daily continuously; may increase to 15 mg after 3 cycles if tolerated
-
CrCl 30–60 → 5 mg once daily
-
CrCl <30, no dialysis → 2.5 mg once daily
-
CrCl <30, dialysis → 2.5 mg once daily after dialysis
-
Combination therapy: choose starting dose by CrCl and clinical status
-
Fit / ECOG 0–1, CrCl >60 → start 25 mg Days 1–21/28
(ECOG 0–1, CrCl > 60 mL/min) Start 25 mg once daily Days 1–21 of a 28-day cycle
-
Older/frail, CrCl >60 → consider 5–10 mg; reassess tolerance
(e.g., age > 80, poor ECOG or functional status, CrCl > 60 mL/min) Consider starting 5 mg or 10 mg once daily Escalate if tolerating well and performance status improved, or keep at same dose depending on clinical context. Faculty practice approach
-
CrCl 30–60 → 10 mg daily; consider 15 mg after 2 cycles
-
CrCl <30, no dialysis → 15 mg every other day
-
CrCl <30, dialysis → 5 mg daily after dialysis
-
Faculty practice: ≤10 mg long term when tolerability limits escalation
≤ 10 mg for long-term maintenance due to tolerability.
-
Dose Modifications: Toxicity develops → hold, resume or reduce by treatment phase
Hematologic toxicity (combination therapy): hold if ANC < 1,000/µL or platelets < 30,000/µL. Resume at same or reduced dose based on recovery and clinical context. Non-hematologic toxicity (e.g., rash, diarrhea, fatigue): hold for Grade ≥ 3 or intolerable Grade 2, then resume at same or reduced dose. Recurrent toxicity: consider further dose reduction or discontinuation.
-
Practical monitoring and safety
Monitor CBC, renal function, VTE risk and tolerability CBC regularly (e.g., at least every 2 weeks during initial cycles, then monthly). Renal function at baseline and with each cycle (and with intercurrent illness). Assess for non-hematologic toxicities. Monitor for thromboembolic events. Review concomitant medications (e.g., strong CYP1A2 inhibitors). Patient Safety: REMS + pregnancy prevention + thromboprophylaxis Lenalidomide is REMS/teratogenic: ensure pregnancy prevention measures according to local requirements. Use thromboprophylaxis based on regimen and individual VTE risk (e.g., aspirin for low risk; LMWH or full anticoagulation for higher risk). Educate patients on early reporting of symptoms (e.g., rash, fatigue, thrombotic events, infection).